| Ritu Mathur, DPM | |
|
388 Garden Ave Ste 120, Holland, MI 49424-8999 | |
| (616) 201-3334 | |
| Not Available |
| Full Name | Ritu Mathur |
|---|---|
| Gender | Female |
| Speciality | Podiatry |
| Experience | 34 Years |
| Location | 388 Garden Ave Ste 120, Holland, Michigan |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1801833512 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 213E00000X | Podiatrist | 5901001716 (Michigan) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Holland Community Hospital | Holland, MI | Hospital |
| Spectrum Health | Grand rapids, MI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Foot And Ankle Specialists Of West Michigan P L L C | 2769475441 | 11 |
News Archive
Glycos Biotechnologies, Inc. (GlycosBio), an emerging biochemical company pioneering metabolic engineering and microbiology innovations for the production of sustainable biochemicals, today exchanged definitive agreements with Malaysian Bio-XCell for the establishment of the Company's industrial biochemical plant and biotechnology R&D facility in Malaysia
Plasma levels of proneurotensin are associated with the development of diabetes, cardiovascular disease, cardiovascular and total mortality, and breast cancer in women during long-term follow-up, according to a study in the October 10 issue of JAMA.
The notion that cutting or burning oneself could provide relief from emotional distress is difficult to understand for most people, but it is an experience reported commonly among people who compulsively hurt themselves.
Alkermes, Inc. today announced positive preliminary results from a phase 3 clinical trial of naltrexone for extended-release injectable suspension (XR-NTX) for the treatment of opioid dependence. The six-month phase 3 study met its primary efficacy endpoint and data showed that patients treated once-monthly with XR-NTX demonstrated statistically significant higher rates of clean (opioid-free) urine screens, compared to patients treated with placebo, as measured by the cumulative distribution of clean urine screens (p<0.0002).
Passport Health, in partnership with vaccine manufacturer PaxVax, Inc. is participating in a clinical study to test the effects of the oral typhoid vaccination, Vivotif (Typhoid Vaccine Live Oral Ty21a). The study will look at the side effects that could occur when taking Vivotif across the range of approved potencies.
› Verified 1 days ago
| Provider Name | Holland Community Hospital |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1780888099 PECOS PAC ID: 0446157291 Enrollment ID: O20031218000484 |
News Archive
Glycos Biotechnologies, Inc. (GlycosBio), an emerging biochemical company pioneering metabolic engineering and microbiology innovations for the production of sustainable biochemicals, today exchanged definitive agreements with Malaysian Bio-XCell for the establishment of the Company's industrial biochemical plant and biotechnology R&D facility in Malaysia
Plasma levels of proneurotensin are associated with the development of diabetes, cardiovascular disease, cardiovascular and total mortality, and breast cancer in women during long-term follow-up, according to a study in the October 10 issue of JAMA.
The notion that cutting or burning oneself could provide relief from emotional distress is difficult to understand for most people, but it is an experience reported commonly among people who compulsively hurt themselves.
Alkermes, Inc. today announced positive preliminary results from a phase 3 clinical trial of naltrexone for extended-release injectable suspension (XR-NTX) for the treatment of opioid dependence. The six-month phase 3 study met its primary efficacy endpoint and data showed that patients treated once-monthly with XR-NTX demonstrated statistically significant higher rates of clean (opioid-free) urine screens, compared to patients treated with placebo, as measured by the cumulative distribution of clean urine screens (p<0.0002).
Passport Health, in partnership with vaccine manufacturer PaxVax, Inc. is participating in a clinical study to test the effects of the oral typhoid vaccination, Vivotif (Typhoid Vaccine Live Oral Ty21a). The study will look at the side effects that could occur when taking Vivotif across the range of approved potencies.
› Verified 1 days ago
| Provider Name | Foot & Ankle Specialists Of West Michigan P L L C |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1154460962 PECOS PAC ID: 2769475441 Enrollment ID: O20040407000902 |
News Archive
Glycos Biotechnologies, Inc. (GlycosBio), an emerging biochemical company pioneering metabolic engineering and microbiology innovations for the production of sustainable biochemicals, today exchanged definitive agreements with Malaysian Bio-XCell for the establishment of the Company's industrial biochemical plant and biotechnology R&D facility in Malaysia
Plasma levels of proneurotensin are associated with the development of diabetes, cardiovascular disease, cardiovascular and total mortality, and breast cancer in women during long-term follow-up, according to a study in the October 10 issue of JAMA.
The notion that cutting or burning oneself could provide relief from emotional distress is difficult to understand for most people, but it is an experience reported commonly among people who compulsively hurt themselves.
Alkermes, Inc. today announced positive preliminary results from a phase 3 clinical trial of naltrexone for extended-release injectable suspension (XR-NTX) for the treatment of opioid dependence. The six-month phase 3 study met its primary efficacy endpoint and data showed that patients treated once-monthly with XR-NTX demonstrated statistically significant higher rates of clean (opioid-free) urine screens, compared to patients treated with placebo, as measured by the cumulative distribution of clean urine screens (p<0.0002).
Passport Health, in partnership with vaccine manufacturer PaxVax, Inc. is participating in a clinical study to test the effects of the oral typhoid vaccination, Vivotif (Typhoid Vaccine Live Oral Ty21a). The study will look at the side effects that could occur when taking Vivotif across the range of approved potencies.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Ritu Mathur, DPM 2144 E Paris Ave Se Ste 100, Grand Rapids, MI 49546-6117 Ph: (616) 494-4251 | Ritu Mathur, DPM 388 Garden Ave Ste 120, Holland, MI 49424-8999 Ph: (616) 201-3334 |
News Archive
Glycos Biotechnologies, Inc. (GlycosBio), an emerging biochemical company pioneering metabolic engineering and microbiology innovations for the production of sustainable biochemicals, today exchanged definitive agreements with Malaysian Bio-XCell for the establishment of the Company's industrial biochemical plant and biotechnology R&D facility in Malaysia
Plasma levels of proneurotensin are associated with the development of diabetes, cardiovascular disease, cardiovascular and total mortality, and breast cancer in women during long-term follow-up, according to a study in the October 10 issue of JAMA.
The notion that cutting or burning oneself could provide relief from emotional distress is difficult to understand for most people, but it is an experience reported commonly among people who compulsively hurt themselves.
Alkermes, Inc. today announced positive preliminary results from a phase 3 clinical trial of naltrexone for extended-release injectable suspension (XR-NTX) for the treatment of opioid dependence. The six-month phase 3 study met its primary efficacy endpoint and data showed that patients treated once-monthly with XR-NTX demonstrated statistically significant higher rates of clean (opioid-free) urine screens, compared to patients treated with placebo, as measured by the cumulative distribution of clean urine screens (p<0.0002).
Passport Health, in partnership with vaccine manufacturer PaxVax, Inc. is participating in a clinical study to test the effects of the oral typhoid vaccination, Vivotif (Typhoid Vaccine Live Oral Ty21a). The study will look at the side effects that could occur when taking Vivotif across the range of approved potencies.
› Verified 1 days ago
Zoe Marie Simaz, DPM Podiatrist Medicare: Medicare Enrolled Practice Location: 904 Washington Ave Ste 130, Holland, MI 49423 Phone: 616-392-7472 Fax: 616-392-3327 | |
Holland Hospital Foot & Ankle Podiatrist Medicare: Not Enrolled in Medicare Practice Location: 3299 N Wellness Dr Ste 230, Holland, MI 49424 Phone: 616-399-1369 Fax: 616-738-7858 | |
Northwood Foot And Ankle Center, Pc Podiatrist Medicare: Medicare Enrolled Practice Location: 388 Garden Ave, Suite 120, Holland, MI 49424 Phone: 616-393-8886 Fax: 616-393-9975 | |
Dr. Patricia S Guisinger, DPM Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 388 Garden Ave, Holland, MI 49424 Phone: 616-393-8886 | |
Dr. Ronald L Morse, D.P.M. Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 334 Washington Blvd, Apt # 2, Holland, MI 49423 Phone: 616-396-5717 | |
Dr. Brent Van Til, DPM Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 904 Washington Ave Ste 130, Holland, MI 49423 Phone: 616-392-7472 Fax: 616-392-3327 | |
Allison Beth Dozeman, DPM Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 904 Washington Ave, Holland, MI 49423 Phone: 616-392-7472 Fax: 616-392-3327 |